UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 17, 2026
Pacira BioSciences, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-35060
|
51-0619477
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2000 Sierra Point Parkway,
Suite 900
Brisbane, California 94005
(Address and Zip Code of Principal Executive Offices)
(650) 242-8052
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
|
PCRX
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Introductory Note
As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger
Agreement”) with Viatris Inc., a Delaware corporation (“Viatris”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Viatris (“Purchaser”).
| Item 1.01 |
Entry into a Material Definitive Agreement.
|
Supplemental Indenture
In connection with the consummation of the Merger (as defined below), the Company and Computershare Trust Company, National Association (the “Trustee”), entered into a
First Supplemental Indenture (the “Supplemental Indenture”), dated as of November 17, 2026, which amends and supplements the Indenture (the “Original Indenture” and, together with the Supplemental Indenture, the “Indenture”), dated as of May 14,
2024, by and between the Company and the Trustee, governing the Company’s 2.125% Convertible Senior Notes due 2029 (the “Notes”), of which $287.5 million in aggregate principal amount is outstanding as of the date hereof.
The Supplemental Indenture provides that, among other things, from and after the Effective Time (as defined below), the right to convert each $1,000 principal amount of
Notes into Shares (as defined below) has been changed into a right to convert such principal amount of Notes solely into Reference Property (as defined in the Indenture) consisting of cash equal to $36.50 multiplied by the Conversion Rate in effect
on the relevant Conversion Date (including, for conversions in connection with the Make-Whole Fundamental Change, any Additional Shares (each as defined in the Indenture)), payable on the tenth Business Day following such Conversion Date. The
Merger, pursuant to which the Shares were converted solely into the right to receive cash, constitutes a Common Stock Change Event, a Make-Whole Fundamental Change, a Fundamental Change and an Exempted Fundamental Change (each as defined in the
Indenture) with respect to the Notes. In connection with the Merger, the Company elected to rely on Section 14.05 of the Indenture and will not offer to repurchase any Notes in connection with the Merger.
Unwind Agreements in respect of the Capped Call Transactions
As previously disclosed, in connection with the issuance of the Notes, the Company entered into capped call transactions (the “Capped Call Transactions”) with certain
financial institution counterparties (the “Capped Call Counterparties”), as evidenced by the confirmations, additional confirmations and related side letters and additional side letters (together, the “Capped Call Confirmations”). On November 17,
2026, the Company entered into an unwind agreement for each Capped Call Confirmation with each Capped Call Counterparty in exchange for an agreed upon cash payment by such Capped Call Counterparty to the Company, payable on or about November 17,
2026.
The foregoing description of the Indenture and the Capped Call Transactions does not purport to be complete and is subject to, and qualified in its entirety by, the full
text of the Original Indenture, which was filed as Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 14, 2024 (the “May 14, 2024 Form 8-K”), and is incorporated into
this Item 1.01 by reference, the full text of a form of the Capped Call Confirmation, which was filed as Exhibit 10.1 of the May 14, 2024 Form 8-K, and is incorporated into this Item 1.01 by reference, and the full text of the Supplemental
Indenture, which is filed as Exhibit 4.1 hereto and incorporated into this Item 1.01 by reference.
|
Item 1.02
|
Termination of Material Definitive Agreement.
|
In connection with the consummation of the Merger, on November 17, 2026, $96,392.50, which represented all amounts outstanding under the Credit Agreement, dated as of
July 3, 2025, by and among the Company, the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank (as amended, restated, or otherwise modified from time to
time, the “Credit Agreement”), was repaid in full, the Credit Agreement and all commitments thereunder were terminated and all liens securing obligations under the Credit Agreement will be released.
The foregoing description of the Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Credit
Agreement, which was filed as Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 7, 2025, and is incorporated into this Item 1.02 by reference.
| Item 2.01 |
Completion of Acquisition or Disposition of Assets.
|
As previously disclosed, pursuant to the Merger Agreement, on October 30, 2026, Purchaser commenced a tender offer to acquire all of the outstanding shares of common
stock of the Company, $0.001 par value per share (the “Shares”), at an offer price of $36.50 per Share in cash, net of applicable withholding taxes and without interest (the “Offer Price”), upon the terms and subject to the conditions set forth in
the Offer to Purchase, dated October 30, 2026 (as amended or supplemented from time to time, the “Offer to Purchase”), and in the related Letter of Transmittal (which, together with the Offer to Purchase and other related materials, as amended or
supplemented from time to time, constituted the “Offer”).
On November 17, 2026, Viatris announced that the Offer and related withdrawal rights had expired as scheduled at one minute following 11:59 p.m., Eastern Time, on
November 16, 2026 (the “Expiration Date”) and the Offer was not extended, and that as of such time, based on the information provided by the depositary and paying agent for the Offer, a total of 32,929,780 Shares, together with the Shares then
owned by Purchaser and its “affiliates” (as such term is defined in Section 251(h)(6)(a) of the General Corporation Law of the State of Delaware (the “DGCL”)), were validly tendered (and not properly withdrawn) pursuant to the Offer prior to the
Expiration Date (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received,” as such term is defined in Section 251(h)(6)(f) of the DGCL, by the “depository,” as such term is defined in Section
251(h)(6)(c) of the DGCL), representing approximately 66.46% of the issued and outstanding Shares as of the Expiration Date.
Accordingly, the number of Shares validly tendered (and not properly withdrawn) and received by the depositary pursuant to the Offer, together with the Shares then owned
by Purchaser and its affiliates, satisfied the Minimum Condition (as defined in the Merger Agreement), and all other conditions to the consummation of the Offer had been satisfied or waived. As a result of the satisfaction of the Minimum Condition
and each of the other conditions to the Offer, on November 17, 2026, Purchaser irrevocably accepted for payment all Shares that were validly tendered (and not properly withdrawn) pursuant to the Offer.
Following the consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied or waived, and the parties to the Merger
Agreement consummated the Merger on November 17, 2026. Pursuant to the Merger Agreement, at the date and time of the filing of the certificate of merger with the Secretary of State of the State of Delaware (the “Effective Time”), Purchaser was
merged with and into the Company (the “Merger”), without a vote on the adoption of the Merger Agreement by the Company’s stockholders, in accordance with Section 251(h) of the DGCL, with the Company continuing as the surviving corporation of the
Merger (the “Surviving Corporation”) and as a wholly owned subsidiary of Viatris. At the Effective Time and as a result of the Merger, each Share issued and outstanding immediately prior to the Effective Time (other than Shares held (i) by the
Company or its subsidiaries (including Shares held in the Company’s treasury), (ii) by Viatris, Purchaser, or any other direct or indirect wholly owned subsidiary of Viatris, or (iii) by stockholders of the Company who have properly exercised and
perfected their statutory rights of appraisal under the DGCL) was automatically converted into the right to receive the Offer Price.
Pursuant to the terms of the Merger Agreement, each option to purchase Shares (each, a “Company Option”) that was outstanding as of immediately prior to the Effective
Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (i) the total number of
Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Company Option, subject to applicable tax withholdings; provided, that any Company Option that had an exercise price per Share that was greater than
or equal to the Offer Price was canceled at the Effective Time without any consideration payable (whether in the form of cash or otherwise) therefor, whether before or after the Effective Time.
Pursuant to the terms of the Merger Agreement, each performance share unit award (each, a “Company PSU”) that was outstanding as of immediately prior to the Effective
Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (i) the total number
of Shares issuable in settlement of such Company PSU, which was based on deemed achievement of the applicable performance metrics at 100% of target, as determined in accordance with the applicable Company PSU award agreement, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
Pursuant to the terms of the Merger Agreement, each restricted stock unit award (each, a “Company RSU”) that was outstanding as of immediately prior to the Effective
Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (i) the total number of
Shares issuable in settlement of such Company RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
Pursuant to the terms of the Merger Agreement, each cash-based award granted pursuant to the Company’s cash-based long-term incentive plan (each, a “Company LTIP Award”)
that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive cash in an amount determined by the Company’s board of directors (the
“Board”), pursuant to the terms of the plan, based on actual achievement of the applicable performance metrics (as previously disclosed for awards granted in 2024 and 2025 and at 107.8% of target as of the closing of the Merger for awards granted
in 2026), subject to applicable tax withholdings.
Pursuant to the terms of the Merger Agreement, each restricted cash award (a “Company Restricted Cash Award”) that was outstanding as of immediately prior to the
Effective Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount of cash equal to the sum of (i) any portion
of the Company Restricted Cash Award that was vested, but remained unpaid, as of the Effective Time and (ii) the amount of Unvested Cash (as defined under the applicable Company Restricted Cash Award agreement) with respect to the Company
Restricted Cash Award.
The total amount of funds required to pay for the Shares in the Offer and the Merger and to repay certain indebtedness of the Company, was approximately $1.69 billion.
These amounts exclude (i) fees and expenses related to the Offer and the Merger and (ii) any Company cash and cash equivalents assumed by Viatris. Viatris provided Purchaser with sufficient funds to purchase all Shares accepted for payment pursuant
to the Offer and all Shares purchased in the Merger using Viatris’ available cash on hand and short-term borrowings.
The foregoing description of the Merger Agreement and the related transactions does not purport to be complete and is qualified in its entirety by reference to the full
text of the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the SEC on October 8, 2026, and is incorporated herein by reference.
The disclosure contained under the Introductory Note above is incorporated herein by reference.
| Item 2.04. |
Triggering Events that Accelerate or Increase a Direct Financial Obligations or an Obligation under an Off-Balance Sheet Arrangement.
|
The disclosure contained under the Introductory Note and in Items 1.01, 1.02 and 2.01 above is incorporated herein by reference.
| Item 3.01. |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On November 17, 2026, the Company notified The Nasdaq Global Select Market (“Nasdaq”) of the consummation of the Merger, and requested that Nasdaq (i) halt trading of the
Shares prior to market open on November 17, 2026 and (ii) file with the SEC a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 to effect
the delisting of the Shares from Nasdaq and to deregister the Shares under Section 12(b) of the Exchange Act. In addition, the Company intends to file with the SEC a certification on Form 15 under the Exchange Act requesting the termination of
registration of the Shares under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.
The disclosure contained under the Introductory Note and in Item 2.01 above is incorporated herein by reference.
| Item 3.03. |
Material Modification to Rights of Security Holders.
|
The disclosure contained under the Introductory Note and in Items 1.01, 2.01 and 3.01 above and in Items 5.01 and 5.03 below is incorporated herein by reference.
| Item 5.01. |
Changes in Control of Registrant.
|
The disclosure contained under the Introductory Note and in Item 2.01 above and in Items 5.02 and 5.03 below is incorporated herein by reference.
As a result of the consummation of the Offer and the Merger pursuant to Section 251(h) of the DGCL, on November 17, 2026, a change in control of the Company occurred. At
the Effective Time, the Company became a wholly owned subsidiary of Viatris.
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, each of Frank D. Lee, Marcelo Bigal, Laura Brege, Christopher Christie, Mark
Froimson, Samit Hirawat, Thomas Wiggans, Michael Yang and Alethia Young ceased serving as a member of the Board and each committee thereof, and each of Frank D. Lee, Shawn Cross, Kristen Williams, Brendan Teehan, Jonathan Slonin and Lauren Riker
ceased serving as an officer of the Company.
Further, in connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, John Miraglia and Michael Rainerman became the officers and directors
of the Surviving Corporation. Information regarding the new officers and directors of the Surviving Corporation had been previously disclosed in the Tender Offer Statement on Schedule TO, filed by Viatris and Purchaser with the SEC on October 30,
2026 (together with the exhibits and annexes thereto and as amended or supplemented from time to time).
| Item 5.03. |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the second amended and restated certificate of incorporation of the Company and
the third amended and restated bylaws of the Company were each amended and restated in their entirety. Copies of the third amended and restated certificate of incorporation of the Company (the “Third A&R Certificate of Incorporation”) and
fourth amended and restated bylaws of the Company (the “Fourth A&R Bylaws”) are filed as Exhibits 3.1 and 3.2 hereto, respectively.
The foregoing description of the Third A&R Certificate of Incorporation and the Fourth A&R Bylaws does not purport to be complete and is subject to, and qualified
in its entirety by, the full text of the Third A&R Certificate of Incorporation and the Fourth A&R Bylaws, which are incorporated into this Item 5.03 by reference.
| Item 7.01 |
Regulation FD Disclosure
|
On November 17, 2026, the Company delivered notice to the holders of the Notes (the “Notice”) announcing that the closing of the Merger constitutes a Common Stock Change
Event, a Make-Whole Fundamental Change, a Fundamental Change and an Exempted Fundamental Change. A copy of the Notice is filed as Exhibit 99.1.
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise
subject to liabilities under that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such
filings.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
|
2.1*
|
Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira
BioSciences, Inc., Viatris Inc. and Peach Purchaser Sub Inc. (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 8, 2026).
|
| |
|
|
3.1
|
Third Amended and Restated Certificate of Incorporation of Pacira BioSciences, Inc.
|
| |
|
|
3.2
|
Fourth Amended and Restated Bylaws of Pacira BioSciences, Inc.
|
| |
|
|
4.1
|
First Supplemental Indenture, dated as of November 17, 2026, by and between Pacira BioSciences, Inc. and Computershare Trust Company, National Association, as trustee.
|
| |
|
|
99.1
|
Notice to Holders of Pacira BioSciences, Inc. 2.125% Convertible Senior Notes Due 2029 of Supplemental Indenture, Common Stock Change Event, Make-Whole Fundamental Change,
Exempted Fundamental Change and Conversion Rights.
|
| |
|
|
104
|
Cover Page Interactive Data File (Formatted as Inline XBRL).
|
| |
|
|
*
|
Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy
of any omitted exhibits or schedules upon request.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
|
| |
|
|
|
Date: November 17, 2026
|
By:
|
|
| |
|
Name: Michael Rainerman
|
| |
|
Title: President
|